C20 Sphingomyelin (d18:1/20:0) – 500 µg

Brand:
Cayman
CAS:
121999-68-6
Storage:
-20
UN-No:
Non-Hazardous - /

C20 Sphingomyelin is a naturally occurring sphingolipid.{40751,37416,37417,37418} Levels of C20 sphingomyelin are upregulated in the hippocampus of rats with diabetes induced by streptozotocin (Item No. 13104) and in human plasma where it is positively correlated with insulin resistance in obese humans.{37416} C20 sphingomyelin is also upregulated in the liver of a mouse model of Niemann-Pick type C1 disease, a neurodegenerative cholesterol-sphingolipid lysosomal storage disorder.{40751} The plasma concentration of C20 sphingomyelin is decreased in men with prostate cancer.{37417} [Matreya, LLC. Catalog No. 1917]  

 

Available on backorder

SKU: 24450 - 500 µg Category:

Description

A sphingolipid; upregulated in the hippocampus of rats with streptozotocin-induced diabetes; positively correlated with insulin resistance in obese humans; upregulated in the liver of a mouse model of Niemann-Pick type C1 disease; plasma concentration is decreased in men with prostate cancer


Formal name: 4-hydroxy-7S-[(1R,2E)-1-hydroxy-2-hexadecen-1-yl]-N,N,N-trimethyl-9-oxo-3,5-dioxa-8-aza-4-phosphaoctacosan-1-aminium, 4-oxide, inner salt

Synonyms:  N-eicosanoyl-D-erythro-Sphingosylphosphorylcholine|SM(d18:1/20:0)

Molecular weight: 759.2

CAS: 121999-68-6

Purity: ≥98%

Formulation: A solid


Product Type|Biochemicals|Lipids|Sphingolipids||Research Area|Cancer||Research Area|Endocrinology & Metabolism|Inborn Errors of Metabolism||Research Area|Endocrinology & Metabolism|Metabolic Diseases|Diabetes||Research Area|Endocrinology & Metabolism|Metabolic Diseases|Obesity||Research Area|Lipid Biochemistry|Sphingolipids